Gemcitabine elaidate

Gemcitabine elaidate (CP-4126) is lipophilic pro-agent of Gemcitabine. Gemcitabine elaidate is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate exhibits anti-tumor activity[1][2].

Product Specifications

CAS Number

[210829-30-4]

Product Name Alternative

CP-4126; CO-101; Gemcitabine 5'-elaidate

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Autophagy; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/gemcitabine-elaidate.html

Purity

98.90

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O[C@@H](C(F)(F)[C@H](N1C(N=C(C=C1)N)=O)O2)[C@H]2COC(CCCCCCC/C=C/CCCCCCCC)=O

Molecular Formula

C27H43F2N3O5

Molecular Weight

527.64

Precautions

H302, H315, H319, H335

References & Citations

[1]Bergman AM, et, al. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs. 2011 Jun;29 (3) :456-66.|[2]Adema AD, et, al. Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel. Int J Oncol. 2010 Jan;36 (1) :285-94.